Market Overview

Sagent Pharma Announces Termporary Importation of Sodium Bicarbonate Injection

Share:
Related SGNT
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity
Benzinga's M&A Chatter for Wednesday January 13, 2016

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced that due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States market, Sagent, in cooperation with the U.S. Food and Drug Administration ("FDA"), has initiated the temporary importation into the U.S. of a non-FDA approved 8.4% Sodium Bicarbonate Injection (1 mEQ/mL) from Phebra Pty Ltd., an Australian manufacturer. Please refer to the Dear Healthcare Provider Letter, posted on the FDA website, for further information about availability of supply.

Posted-In: News

 

Related Articles (SGNT)

View Comments and Join the Discussion!